odevixibat

bile acid transporter inhibitor.

Also Known As:

(2S)-2-(((2R)-2-((((3,3-Dibutyl-7-(methylsulfanyl)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl)oxy)acetyl)amino)-2-(4-hydroxyphenyl)acetyl)amino)butanoic acid; bylvay

Networked: 14 relevant articles (4 outcomes, 5 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Benzazepines: 5
      - Benzodiazepines: 8452
        odevixibat: 14
Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Butyrates: 2613
      - odevixibat: 14
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Butyrates: 2613
      - odevixibat: 14

Experts

1.	Sturm, Ekkehard: 3 articles (01/2022 - 06/2020)
2.	Arnell, Henrik: 2 articles (01/2022 - 01/2021)
3.	Baumann, Ulrich: 2 articles (01/2022 - 01/2021)
4.	Fischler, Björn: 2 articles (01/2022 - 01/2021)
5.	Gonzalès, Emmanuel: 2 articles (01/2022 - 01/2021)
6.	Karpen, Saul J: 2 articles (01/2022 - 09/2020)
7.	Lacaille, Florence: 2 articles (01/2022 - 01/2021)
8.	Mattsson, Jan P: 2 articles (01/2022 - 01/2021)
9.	Thompson, Richard J: 2 articles (01/2022 - 01/2021)
10.	Artan, Reha: 1 article (01/2022)

Related Diseases

1.	Pruritus (Itching) 01/01/2023 - "Treatment with IBAT inhibitor was effective and safe in our patient suggesting that Odevixibat may be potentially considered for the treatment of cholestatic pruritus also in children with rare subtypes of PFIC. " 03/08/2023 - "Odevixibat received its first approval in the European Union (EU) in July 2021 for the treatment of PFIC in patients aged 6 months, followed by approval in the USA in August 2021 for the treatment of pruritus in PFIC patients aged 3 months. " 03/08/2023 - "Odevixibat: A Review of a Bioactive Compound for the Treatment of Pruritus Approved by the FDA." 10/01/2021 - "In July 2021, odevixibat received its first approval in the EU for the treatment of PFIC in patients aged ≥ 6 months, followed shortly by its approval in the USA for the treatment of pruritus in patients aged ≥ 3 months with PFIC. " 08/01/2023 - "Odevixibat in patients with progressive familial intrahepatic cholestasis was generally well tolerated and associated with sustained reductions in sBAs and pruritus. "
2.	progressive familial intrahepatic 1 Cholestasis 11/01/2022 - "Odevixibat: a promising new treatment for progressive familial intrahepatic cholestasis." 08/01/2023 - "The current study, called PEDFIC 2, suggested that odevixibat can improve the problematic signs and symptoms of progressive familial intrahepatic cholestasis and was generally safe for patients." 08/01/2023 - "Interim results from an ongoing, open-label, single-arm trial of odevixibat in progressive familial intrahepatic cholestasis." 01/01/2022 - "Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial." 01/01/2022 - "Positive phase III results for odevixibat for progressive familial intrahepatic cholestasis."
3.	Liver Diseases (Liver Disease) 03/08/2023 - "Oral odevixibat was also studied in children with cholestatic liver disease. " 01/01/2021 - "Oral odevixibat safety, tolerability, and efficacy in pediatric patients with cholestatic liver disease and pruritus were evaluated. " 09/01/2020 - "The clinical programs of 2 IBAT inhibitors in development for the treatment of pediatric cholestatic liver diseases, maralixibat and odevixibat, are highlighted." 01/01/2021 - "Effects of odevixibat on pruritus and bile acids in children with cholestatic liver disease: Phase 2 study." 06/29/2020 - "We describe a 15-month-old male patient with severe pruritus diagnosed with PFIC type 2 enrolled in an open-label phase 2 study who received 4 weeks of treatment with odevixibat, an ileal bile acid transporter inhibitor under development for cholestatic liver disease treatment. "
4.	Alagille Syndrome (Alagille-Watson Syndrome) 05/01/2023 - "This report suggests odevixibat may be an effective treatment option for Alagille syndrome." 05/01/2023 - "Odevixibat Treatment of Alagille Syndrome: A Case Report." 05/01/2023 - "During the course of odevixibat treatment, genetic testing results and additional clinical findings indicated a diagnosis of Alagille syndrome, a condition that shares some clinical features with progressive familial intrahepatic cholestasis. " 03/08/2023 - "Odevixibat is also being evaluated in many countries for the treatment of other cholestatic illnesses, including Alagille syndrome and biliary atresia. " 10/01/2021 - "Odevixibat is also in clinical development for the treatment of other cholestatic diseases, including Alagille syndrome and biliary atresia, in various countries. "
5.	Biliary Atresia 03/08/2023 - "Odevixibat is also being evaluated in many countries for the treatment of other cholestatic illnesses, including Alagille syndrome and biliary atresia. " 10/01/2021 - "Odevixibat is also in clinical development for the treatment of other cholestatic diseases, including Alagille syndrome and biliary atresia, in various countries. " 11/01/2022 - "Odevixibat: an investigational inhibitor of the ileal bile acid transporter (IBAT) for the treatment of biliary atresia."

Related Drugs and Biologics

1.	Bile Acids and Salts (Bile Acids)
2.	bile acid binding proteins
3.	maralixibat
4.	odevixibat
5.	Ursodeoxycholic Acid (Urso)
6.	Rifampin (Rifampicin)